
Arachidonic-acid identity-and-context orientation. Hydrogens are omitted; the plate is not a crystallographic conformation and does not show release, oxidation, eicosanoid synthesis, inflammation, concentration, or treatment effect.
Scientific media record3 verified identifiers
- Subject
- Arachidonic Acidbiological-process
- Review
- Editorial review completeIdentifiers authority-verified · Accessibility validated · · arachidonic-acid|arachidonic-acid-mechanism-v1.webp
- Digital source
- Trained-algorithmic mediaCreated with a trained generative algorithm and reviewed by WikiBiome for subject identity, scientific framing, identifiers, provenance, and accessibility.
- Scientific basis
- Arachidonic Acid — PubChemArachidonic acid — ChEBI
- License
- CC BY-SA 4.0Created
Arachidonic acid (AA) is a 20-carbon omega-6 polyunsaturated fatty acid (20:4n-6) that serves as the primary substrate for prostaglandin and leukotriene synthesis via COX-2 and 5-LOX pathways.
It is the dominant pro-inflammatory lipid mediator—and its balance with anti-inflammatory omega-3 fatty acids (EPA/DHA) determines the inflammatory tone across multiple disease signatures.
Evidence map4 cited passagesInspect provenance +
COX-2/NF-kB axis: Metal-driven NF-kB activation upregulates COX-2, increasing arachidonic acid conversion to pro-inflammatory prostaglandin E2 (PGE2)—the same pathway activated by microbial LPS via TLR4.
NSAIDs and microbiome: NSAIDs (COX inhibitors blocking AA metabolism) cause gut microbiome disruption and intestinal injury, paradoxically increasing dysbiosis while reducing inflammation.
Endometriosis metabolomics: Altered arachidonic acid levels in fecal metabolomics of endometriosis models.
Diabetic ED: Fatty acid profiles including AA altered in diabetic erectile dysfunction.
Microbiome Connection#
COX-2/NF-kB axis: Metal-driven NF-kB activation upregulates COX-2, increasing arachidonic acid conversion to pro-inflammatory prostaglandin E2 (PGE2)—the same pathway activated by microbial LPS via TLR4.[1]Nonsteroidal Anti-Inflammatory Drugs as Therapeutic Allies of the Gut Microbiome on Chronic InflammationFabian Mermans, Evelien Heiremans, Maud Van Belleghem et al. · 2019Open reference 1 ↓
NSAIDs and microbiome: NSAIDs (COX inhibitors blocking AA metabolism) cause Gut Microbiome disruption and intestinal injury, paradoxically increasing Dysbiosis while reducing Metal-Driven Inflammation.[1]Nonsteroidal Anti-Inflammatory Drugs as Therapeutic Allies of the Gut Microbiome on Chronic InflammationFabian Mermans, Evelien Heiremans, Maud Van Belleghem et al. · 2019Open reference 1 ↓
Endometriosis metabolomics: Altered arachidonic acid levels in fecal metabolomics of endometriosis models.[2]Ni 2020 — Fecal Metabolomics and Gut Microbiota Correlation in Endometriosis MiceZhexin Ni, Shuai Sun, Yanli Bi et al. · 2020Open reference 2 ↓ Diabetic ED: Fatty acid profiles including AA altered in diabetic erectile dysfunction.[3]Ben Khedher 2017 — Disturbed Fatty Acids Metabolism in Diabetic Erectile DysfunctionMohamed Raâfet Ben Khedher, Houda Bouhajja, Samia Haj Ahmed et al. · 2017Open reference 3 ↓
Resolution Pathway#
Arachidonic acid is also the precursor for lipoxins—pro-resolving mediators that actively terminate inflammation. The balance between pro-inflammatory (prostaglandins) and pro-resolving (lipoxins) AA metabolites depends on the enzymatic context, which metals can disrupt.
Cross-References#
- inflammation—AA/COX-2 as pro-inflammatory pathway
- Omega-3 Fatty Acids (EPA/DHA)—anti-inflammatory counterbalance to AA
- Lipid Metabolism—broader lipid context
- Lipid Peroxidation—AA as substrate for oxidative damage
- NF-kB Signaling Pathway—NF-kB drives COX-2/AA pathway
References 5
Numbered by first appearance in the article, then reconciled with its declared source list.
- 1
Fabian Mermans, Evelien Heiremans, Maud Van Belleghem et al. (2019). Nonsteroidal Anti-Inflammatory Drugs as Therapeutic Allies of the Gut Microbiome on Chronic Inflammation. Facta Universitatis Series Medicine and Biology.
- 2
Zhexin Ni, Shuai Sun, Yanli Bi et al. (2020). Ni 2020 — Fecal Metabolomics and Gut Microbiota Correlation in Endometriosis Mice. American Journal of Reproductive Immunology.
- 3
Mohamed Raâfet Ben Khedher, Houda Bouhajja, Samia Haj Ahmed et al. (2017). Ben Khedher 2017 — Disturbed Fatty Acids Metabolism in Diabetic Erectile Dysfunction. Lipids in Health and Disease.
- 4
Xinyun Bi, Fanghong Li, Shanshan Liu et al. (2017). Bi 2017 — Omega-3 Polyunsaturated Fatty Acids Ameliorate Type 1 Diabetes and Autoimmunity. Journal of Clinical Investigation.
- 5
Martin DA, Bolling BW (2015). A Review of the Efficacy of Dietary Polyphenols in Experimental Models of Inflammatory Bowel Diseases. Food & Function.
Article network
Connect the evidence
Publicly readable discussion by ORCID-authenticated researchers. Questions, interpretation, methods, corrections, and new evidence stay attached to this record.
No discussion yet. Start with a precise question or a source-backed observation.
Activity and accepted changes
Accepted researcher context, editorial status, public discussion, and upstream Git revisions are shown together. Pending, declined, and withdrawn proposals remain private.
- published revision
Backfill gut microbiome concept links
Karen Pendergrass · +1 −1
Inspect exact Git diff ↗ - published revision
Backfill inflammation concept links
Karen Pendergrass · +2 −2
Inspect exact Git diff ↗ - published revision
Complete corpus-wide Dysbiosis linking
Karen Pendergrass · +1 −1
Inspect exact Git diff ↗ - published revision
massive wiki expansion: 149 stubs fixed, 100+ new pages, Rule 15 scan, keystone papers
WikiBiome Deploy Bot · +43 −0
Inspect exact Git diff ↗

